Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area

 
• By Sten Stovall
  
Oculus
Nightstar develops gene therapies delivered by AAV for rare eye diseases • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business